 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 2 | 1/1 | 返回列表 |
| 查看: 352 | 回復(fù): 1 | |||
ienjoysun銀蟲 (著名寫手)
|
[交流]
Sun Pharma's $3.2bn Ranbaxy acq: 'Compliance first, synergies later' 已有1人參與
|
|
Sun Pharma's $3.2bn Ranbaxy acq: 'Compliance first, synergies later' By Dan Stanton+ 07-Apr-2014 Related tags: Ranbaxy, Sun Pharma, Generics, India, US FDA, Daiichi Sankyo Related topics: Mergers and acquisitions, Regulatory & Safety, Processing, QA/QC, APIs (active pharmaceutical ingredients) Sun Pharma spends $3.2bn to buy troubled manufacturer Ranbaxy from Daiichi Sankyo Regulatory compliance will be the number one focus for Sun Pharma, the company says, following its $3.2bn (?2.3bn) takeover of Indian generics firm Ranbaxy. Sun Pharma made the comments during a conference call this morning in response to questions about the wisdom of buying Ranbaxy from Japanese drugmaker, Daiichi Sankyo. Investors asked about the pricetag in light of the US import ban on drugs and active pharmaceutical ingredients (API) made at Ranbaxy's plants in Toansa , Paonta Sahib, Dewas and Mohali in India. Others raised the consent decree the firm has been operating under since 2012 as a concern. Managing Director Dilip Shanghvi agreed that Ranbaxy had ??faced manufacturing challenges,?? contributing to the net loss over the past three years , but said Sun Pharma believed ??the valuation is justified?? based on the firm's underlying business in India and emerging markets. Company spokesperson Uday Baldota told in-Pharmatechnologist.com that whilst it was "difficult to give specifics at this stage," it is "suffice to say that we have resolved a consent decree situation in the past." Furthermore the company told us the deal would ??see tremendous growth opportunities especially in ROW [rest of the world] and India markets,?? adding Sun is confident it ??can create lasting value for our shareholders through the combined entity.?? Compliance in US market According to its own report, Sun Pharma??s business is geographically split with 60% of its products destined for the US market, 23% for India and 17% for the ROW. Ranbaxy??s market, meanwhile, is 50% of ROW, 21% India and 29% US-focused. Following the merger the company anticipates US sales of over $2bn, representing 47% of its revenue. For this to happen, the company has acknowledged the US regulatory issues. ??Our focus will be to address the issue of achieving compliance,?? Shanghvi said, adding that a predicted $250m of revenue and operational synergies by 3rd year would not come from the manufacturing side. ??Energy has to be focused on achieving compliance,?? he added. ??At this point I??d prefer not to give specific timelines about compliance, all I can promise is it will be the most important focus for the management to follow.?? ??Better to go out now?? Ranbaxy owner Daiichi Sankyo did not respond to attempts by this publication for further comment regarding the sale. However former Ranbaxy Executive Director Ramesh Adige told New Delhi Television Daiichi ??must have thought that they can't settle the problems of this company and its better to go out now.?? ??This is the right time for Sun Pharma to buy Ranbaxy,?? he continued. ??Ranbaxy's problem with from the US Food and Drug Administration (FDA) cannot get more intense than they are already, things can only improve from now onwards.?? However, for now the bad news continues to come for Ranbaxy with the firm announcing the US Attorney's Office for the District of New Jersey has issued an administrative subpoena dated March 13, seeking information regarding the Toansa facility and the inspection that led to January??s import alert. Sun Chairman Israel Makov told stakeholders this morning ??Daiichi Sankyo has agreed to indemnify Sun Pharma and Ranbaxy for, among other things, certain costs and expenses that may arise?? from the subpoena, as part of the transaction. Copyright - Unless otherwise stated all contents of this web site are © 2014 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions |
回復(fù)此樓» 猜你喜歡
硅膠柱可以用純二氯甲烷洗脫嗎
已經(jīng)有18人回復(fù)
-
博導(dǎo)推薦
已經(jīng)有2人回復(fù)
-
藥理學(xué)論文潤色/翻譯怎么收費(fèi)?
已經(jīng)有129人回復(fù)
-
哪里做甘氨酸受體與配體結(jié)合率的試驗(yàn)
已經(jīng)有0人回復(fù)
-
腦梗怎么治療
已經(jīng)有3人回復(fù)
-
腦梗怎么治療
已經(jīng)有0人回復(fù)
-
生物組織中有目標(biāo)分析物，專屬性怎么做
已經(jīng)有0人回復(fù)
-
關(guān)于SCI雜志發(fā)表掛名
已經(jīng)有32人回復(fù)
lunar3809
榮譽(yù)版主 (文壇精英)
禁蟲
- DRDEPI: 1
- 應(yīng)助: 3 (幼兒園)
- 貴賓: 0.33
- 金幣: 1946.8
- 散金: 6556
- 紅花: 28
- 沙發(fā): 96
- 帖子: 25871
- 在線: 1256.1小時(shí)
- 蟲號: 696060
- 注冊: 2009-02-04
- 性別: GG
- 專業(yè): 藥物化學(xué)
- 管轄: 有機(jī)交流
2樓2014-04-08 11:55:53
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 ienjoysun 的主題更新
| 2 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 317求調(diào)劑 +3 | 申子申申 2026-03-19 | 6/300 |
|
|---|---|---|---|---|
|
|
[考研] 328求調(diào)劑，英語六級551，有科研經(jīng)歷 +4 | 生物工程調(diào)劑 2026-03-16 | 12/600 |
|
|
|
[考研] 【同濟(jì)軟件】軟件（085405）考研求調(diào)劑 +3 | 2026eternal 2026-03-18 | 3/150 |
|
|
[考研] 26調(diào)劑/材料/英一數(shù)二/總分289/已過A區(qū)線 +7 | 步川酷紫123 2026-03-13 | 7/350 |
|
|
|
[考研] 295求調(diào)劑 +3 | 一志愿京區(qū)211 2026-03-18 | 5/250 |
|
|
|
[考研] 311求調(diào)劑 +11 | 冬十三 2026-03-15 | 12/600 |
|
|
|
[考研] 0703化學(xué)調(diào)劑 +3 | 妮妮ninicgb 2026-03-17 | 3/150 |
|
|
|
[考研] 334求調(diào)劑 +3 | 志存高遠(yuǎn)意在機(jī)?/a> 2026-03-16 | 3/150 |
|
|
|
[基金申請] 被我言中：新模板不強(qiáng)調(diào)格式了，假專家開始管格式了 +4 | beefly 2026-03-14 | 4/200 |
|
|
|
[考研] 308求調(diào)劑 +4 | 是Lupa啊 2026-03-16 | 4/200 |
|
|
|
[考研] 290求調(diào)劑 +3 | p asserby. 2026-03-15 | 4/200 |
|
|
|
[考研] 211本，11408一志愿中科院277分，曾在中科院自動(dòng)化所實(shí)習(xí) +6 | Losir 2026-03-12 | 7/350 |
|
|
|
[考研] 302求調(diào)劑 +4 | 小賈同學(xué)123 2026-03-15 | 8/400 |
|
|
|
[考研] 274求調(diào)劑 +5 | 時(shí)間點(diǎn) 2026-03-13 | 5/250 |
|
|
|
[考研] 326求調(diào)劑 +4 | 諾貝爾化學(xué)獎(jiǎng)覬?/a> 2026-03-15 | 7/350 |
|
|
|
[考研] 304求調(diào)劑 +4 | ahbd 2026-03-14 | 4/200 |
|
|
|
[考研] 318求調(diào)劑 +3 | Yanyali 2026-03-15 | 3/150 |
|
|
|
[考研] 304求調(diào)劑 +3 | 曼殊2266 2026-03-14 | 3/150 |
|
|
|
[考研] 289求調(diào)劑 +4 | 這么名字咋樣 2026-03-14 | 6/300 |
|
|
|
[考博] 福州大學(xué)楊黃浩課題組招收2026年專業(yè)學(xué)位博士研究生，2026.03.20截止 +3 | Xiangyu_ou 2026-03-12 | 3/150 |
|